NEW HAVEN, Conn., May 29, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
– ARV-471 demonstrates evidence of anti-tumor activity, and potential for best-in-class safety, and estrogen receptor (ER) degradation profile and robust efficacy signals in a heavily pretreated ...
Arvinas is pushing ahead with plans to expand development of its prostate cancer prospect ARV-766 into earlier-line settings. The biotech linked the protein degrader to declines in the PSA biomarker ...
– 42% of patients with AR ligand binding domain (LBD) mutations achieved PSA 50; in patients with AR L702H mutations, 3 of 5 achieved PSA 50 – – ARV-766 was well-tolerated, and activity in a heavily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results